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The maintenance of self-renewal in stem cells appears
to be distinct from the induction of proliferation of the
terminally differentiated mammalian cardiomyocytes
because it is believed that the latter are unable to di-
vide. However, proliferation is a necessary step in
both processes. Interestingly, the small molecule 6-
bromoindirubin-30-oxime (BIO) is the first pharmaco-
logical agent shown to maintain self-renewal in hu-
man and mouse embryonic stem cells. To determine
whether amolecule that canmaintain stem cell proper-
ties can also participate in controlling the proliferative
capability of the highly differentiated cardiomyocytes,
we examine the effect of BIO in postmitotic cardiac
cells. Here, we show that BIO promotes proliferation
in mammalian cardiomyocytes. Our demonstration of
a second role for BIO suggests that the maintenance
of stem cell self-renewal and the induction of prolifer-
ation in differentiated cardiomyocytesmay share com-
mon molecular pathways.
Introduction
Heart disease results in the loss of cardiomyocytes and
is a leading cause of death [1]. It has been a significant
challenge to develop effective treatments for cardiac
repair because adult mammalian cardiomyocytes are
highly differentiated cells and have been believed to
be unable to proliferate. Mammalian cardiomyocytes
withdraw from the cell cycle soon after birth and have
lowered levels of Cyclin A [2]. The fact that primary car-
diac tumors rarely occur supports the notion that adult
cardiomyocytes are highly restricted in their ability to
divide. Because of its lack of proliferative potential, the
primary response of the mammalian heart to injury is
scar formation, which prevents cardiac repair. Thus,
the loss of cardiomyocytes after damage caused by
events such as myocardial infarction generally results
in a compensatory response that is inadequate to
restore function. Current therapies are also limited in
their effectiveness. In order to sufficiently repair cardiac
injury, it is necessary to provide a source of new cardio-
myocytes.
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been to identify and expand cardiac stem and/or pro-
genitor cells, or to utilize known stem cell populations
to generate functional cardiomyocytes [3, 4]. However,
the difficulty in identifying cardiomyocytes derived from
these transplanted sources in animal models raises the
question of whether this approach will result in effective
therapy. Alternatively, we have sought to identify path-
ways that could induce proliferation of cardiomyocytes
as a potential route to restore cardiac function. Re-
cently, our laboratory has shown that proliferation in
differentiated rat cardiomyocytes can be achieved [5].
Interestingly, the maintenance of self-renewal in stem
cells has generally been thought of as a process that is
distinct from that of the induction of proliferation in post-
mitotic mammalian cardiomyocytes even though the
requirement for proliferation is a necessary step in both
events. Whether these two processes share common
molecular pathways is an important question that has
not been addressed by existing studies and has strong
implications for future therapeutic approaches. The re-
cently identified small molecule 6-bromoindirubin-30-
oxime (BIO) [6], a specific inhibitor of glycogen synthase
kinase-3 (GSK-3), has been shown to maintain self-re-
newal and pluripotency in human and mouse embryonic
stem cells (ESCs) [7]. Treatment of ESCs with BIO results
in increased b-catenin activity, indicating that activation
of canonical Wnt signaling promotes maintenance of
stem cell properties [7]. The characterization of the func-
tion of BIO in ESCs has therefore allowed us to examine
the question of whether a molecule that can maintain
stem cell properties can also participate in controlling
the proliferative capability of the highly differentiated
cardiomyocyte. Here, we show that BIO promotes prolif-
eration in mammalian cardiomyocytes. Stimulation of
neonatal rat cardiomyocytes with BIO induced S phase
entry and the upregulation of positive cell cycle regula-
tors, while the level of the CDK inhibitor p27 was de-
creased. BIO treatment elevated b-catenin activity in
cardiomyocytes, suggesting that the increase in prolif-
erative ability may be due, in part, to the activation of
the canonical Wnt pathway. In both neonatal and adult
rat cardiomyocytes, BIO stimulation promoted cell cycle
progression and increased the number of mitoses. Our
demonstration of a second role for BIO suggests that
the maintenance of stem cell self-renewal and the induc-
tion of proliferation in differentiated cardiomyocytes
may share common molecular pathways.
Results
BIO Stimulates Neonatal Cardiomyocytes
to Enter S Phase
To assess the ability of BIO to induce cell cycle entry in
neonatal cardiomyocytes, cells were treated once with
increasing concentrations of the small molecule for
48 hr and were pulse labeled with 5-bromo 20-deoxy-uri-
dine (BrdU) for the last 24 hr. BrdU can be incorporated
during DNA synthesis in lieu of thymidine and thus has
been used as a marker for S phase entry. To distinguish
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with an antibody to sarcomeric tropomyosin. Neonatal
cardiomyocytes stimulated with the control compound
dimethyl sulfoxide (DMSO) incorporated BrdU in
4.9%6 1.9% (mean6 SD) of cells assayed, as detected
by immunofluorescence staining. In the presence of
5 mM BIO, 51.7% 6 3.6% of cardiomyocytes assayed
showed BrdU incorporation, representing an approxi-
mate 10-fold increase when compared to the control
(p = 0.0004) (Figure 1A and Table S1; see the Supple-
mental Data available with this article online). The ability
of BIO to stimulate BrdU incorporation was dosage de-
pendent, and a maximum effect was seen at 5 mM, dem-
onstrating that this effect is specific to the compound. At
concentrations of 10 mM or greater, cell toxicity is ob-
served, resulting in decreased BrdU incorporation. In
addition, treatment of cells with 1-methyl-BIO (MeBIO),
a kinase-inactive analog of BIO that does not inhibit
GSK-3 activity [6], failed to induce BrdU incorporation
in cells (Figure 1A). To further verify the specificity of
BIO action, we also tested the ability of a cell-permeable
and substrate-competitive peptide inhibitor of GSK-3 [8]
to induce S phase entry. Cells treated with the GSK-3
peptide inhibitor and labeled with BrdU for 72 hr showed
a 2-fold increase in BrdU incorporation (26.8% 6 6.7%)
when compared to control (14.6% 6 2.2%, p = 0.037)
(Figure 1C). Thus, the ability of BIO to promote S phase
entry is dependent upon its inhibition of the kinase
activity of GSK-3.
Stimulation with BIO Increases the Levels
of Positive Cell Cycle Regulators
in Neonatal Cardiomyocytes
To better understand the effect of BIO on neonatal car-
diomyocyte proliferation in vitro, we assayed changes in
protein levels of genes associated with cell proliferation
by using immunofluoresence staining. As expected,
stimulation of cells with MeBIO showed effects similar
to control (Figure 2A). In contrast, the percentage of cells
expressing high levels of Ki67, a proliferation marker [9],
increased by 20-fold compared to control (1.7% 6
1.1%, p = 0.01) when stimulated with BIO (34.7% 6
13.8%) (Figure 2A).
Previous studies have shown that levels of cyclins are
decreased in neonatal cardiomyocytes [5, 10]. In mouse
fibroblasts, GSK-3b can directly phosphorylate Cyclin
D1, leading to its degradation [11]. In addition, targeting
of Cyclin D1 and CDK4 to the nucleus was sufficient to
induce cell cycle entry in neonatal rat cardiomyocytes,
and the expression of a dominant-negative form of
GSK-3b in cardiomyocytes resulted in an increase in nu-
clear accumulation of Cyclin D1 [12]. Treatment with BIO
increased the percentage of cardiomyocytes express-
ing Cyclin D1 by 13-fold (16.4% 6 1.8%) compared to
control (1.3%6 0.2%, p = 0.0001) (Figure 2A). Moreover,
the increase in Cyclin D1 level was detected in the nu-
cleus (Figure 2B). Similarly, Cyclin A mRNA and protein
levels have been shown to rapidly decrease in rat hearts
postbirth such that it is undetectable in adults [2, 13].
Treatment with BIO also increased the percentage of
cells that show strong Cyclin A expression in cardio-
myocytes by 13-fold (13.9% 6 1.6%) compared to con-
trol (1.1%6 0.7%, p = 0.0002). The CDK inhibitor p27 is a
negative regulator of cell cycle progression that is highlyexpressed in rat hearts postbirth and has been hypoth-
esized to act as a block in cardiomyocyte cell cycle
re-entry [14–16]. When treated with BIO, the number of
cells that stain positively for p27 diminished by 22-fold
(2.1% 6 1.7%) compared to control (47.2% 6 11.1%,
p = 0.002) (Figure 2A). Together, our data suggest that
BIO has the ability to promote cell cycle progression
by increasing the levels of positive cell cycle regulators
and decreasing the level of a negative effector.
Stimulation of Neonatal Cardiomyocytes with BIO
Induces Cell Division
Our previous work has demonstrated that stimulation of
neonatal cardiomyocytes with FGF1 is sufficient to in-
duce S phase entry, but passage through mitosis and
cytokinesis requires the concomitant inhibition of p38
kinase activity [5]. This result suggests that perhaps
modulation of multiple pathways is needed to achieve
proliferation. To determine whether BIO is sufficient to
promote cell division, we assayed for G2/M progression
by staining for phospho-Histone H3 (H3P), a marker of
mitosis. BIO-stimulated cells (2.25% 6 0.74%) showed
a 5-fold increase in the percentage of H3P-positive cells
over control (0.42 6 0.09; p = 0.013) (Figure 2C). We
Figure 1. BIO Induces S Phase Entry in Neonatal Cardiomyocytes
(A) Neonatal cardiomyocytes were stimulated with either DMSO
(control), MeBIO (kinase-inactive small molecule), or BIO for 48
hr, pulsed with BrdU from 24–48 hr, fixed, and stained to detect
DNA synthesis. BIO stimulates BrdU incorporation in a dosage-de-
pendent manner (mean 6 SD). The optimal effect was achieved at
5 mM BIO and represents a 10-fold increase over the control.
(B) Stainings of neonatal cardiomyocytes treated with either DMSO
(control) or 5 mM BIO in the same conditions as those described in
(A) to detect DNA synthesis (anti-BrdU, green) and cardiomyocytes
(anti-tropomyosin, red). DAPI (blue) stains nuclei. The scale bar is
50 mm.
(C) Neonatal cardiomyocytes were stimulated with either DMSO
(control) or 20 mM GSK-3 peptide inhibitor and labeled with BrdU
for 72 hr. Cells treated with the GSK-3 peptide inhibitor showed
a 2-fold increase in BrdU incorporation when compared to control.
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(A and B) BIO stimulation promotes cell cycle progression in neonatal cardiomyocytes. Neonatal cardiomyocytes were stimulated with DMSO
(control), 5 mM MeBIO, or 5 mM BIO for 48 hr. (A) A greater percentage of cells that were stimulated with BIO showed highly elevated levels of
Ki67, Cyclin A, and Cyclin D1 and decreased levels of the CDK inhibitor p27 when compared to control (mean 6 SD). (B) Examples of cardi-
omyocytes stained with tropomyosin (red) or Troponin I (red) that show increased expression of Ki67, Cyclin D1, and Cyclin A (green) as com-
pared to control. BIO-stimulated cells showed significantly lowered levels of p27 (green) expression. DAPI staining is shown in blue. The scale
bar is 50 mm.
(C and D) Neonatal cardiomyocytes were stimulated with DMSO (control) or 5 mM BIO for 3 days and were assayed for karyokinesis. The scale
bar is 20 mm. (C) Treatment with BIO showed a 5-fold increase in the number of mitoses when compared to control (mean 6 SD). (D) Visual-
ization of BIO-treated cardiomyocytes identified by tropomyosin staining (red) undergoing stages of mitosis marked by phospho-Histone H3
antibody (green), including prophase, metaphase, and anaphase. Cardiomyocytes undergoing cytokinesis after BIO treatment (tropomyosin,
red; DAPI, blue). The cleavage furrow is marked by Aurora B staining (yellow).observed BIO-treated cells undergoing all phases of
mitosis, including prophase, metaphase, and anaphase
(Figure 2D). To further confirm that BIO-treated cells are
capable of cell division, we assayed for cytokinesis by
performing immunostaining with anti-Aurora B (AurB)
antibody [5]. AurB is a mitotic protein kinase that is
involved in chromosome segregation and is essential
for cytokinesis, during which it is located at the midbody
[17]. AurB staining showed that BIO-stimulated cells
formed contractile rings and can undergo proper cytoki-
nesis (Figure 2D).
BIO Increases b-Catenin Activity in Cardiomyocytes
BIO has been shown to reduce GSK-3b kinase activity
and thus signal through the canonical Wnt pathway by
causing an increase in b-catenin levels [6]. Stimulation
of the Wnt pathway induces cytoplasmic b-catenin to
translocate to the nucleus, where it acts with T cell factor
(Tcf) to regulate transcription of Wnt target genes [18]. Inother systems, an increase in b-catenin levels, whether
through mutational activation or overexpression, has
been associated with elevated rates of proliferation
[19]. To determine whether the same mechanism exists
in neonatal cardiomyocytes, we stimulated cells with
BIO and examined b-catenin levels. In control cells, b-
catenin staining is weak and appears to concentrate at
cell borders (Figure 3A). In contrast, BIO-stimulated
cells show strong nuclear staining, suggesting that there
is an increased level of b-catenin (Figure 3A). To deter-
mine whether the increase in nuclear accumulation of
b-catenin led to an increase in functional activity, we
performed luciferase assays by using a Tcf reporter
as an indicator of b-catenin transcriptional activity.
Neonatal cardiomyocytes were transfected either with
a wild-type Tcf reporter carrying multimeric Tcf sites
(TOPflash) or a mutant reporter carrying nonfunctional
Tcf sites (FOPflash) [20]. Cells stimulated with BIO
showed significantly higher reporter activity compared
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Neonatal Cardiomyocytes
(A–C) Neonatal cardiomyocytes were treated
with either DMSO (control) or the indicated
compound for 24 hr. (A) BIO treatment
causes nuclear accumulation of b-catenin
(green), which is not observed in control
cells (tropomyosin, red; DAPI, blue). The
scale bar is 50 mm. (B) Cells were assayed
for b-catenin-mediated transcriptional acti-
vation by using a reporter containing either
functional (TOPflash) or mutated (FOPflash)
Tcf binding sites. Cells stimulated with in-
creasing dosages of BIO showed a corre-
sponding rise in the levels of b-catenin ac-
tivity, as measured by luciferase activity
(mean 6 SD). Treatment with 5 mM BIO re-
sulted in the highest fold change (almost 6-
fold) when TOPflash activity was normalized
against FOPflash activity. There was no sig-
nificant difference in activities in the pres-
ence of the mutated FOPflash reporter. Cells
treated with DMSO (control) or MeBIO did
not have a significant effect in modulating
b-catenin activity. (C) Cardiomyocytes were
treated with either DMSO (control) or 20 mM
FRATtide and were labeled with BrdU for
72 hr (mean 6 SD).to control (p < 0.05), indicative of increased b-catenin
function (Figure 3B). Importantly, the increased activity
was dosage dependent and was not observed in cells
transfected with the mutant reporter, FOPflash.
Because elevated b-catenin activity can positively
influence proliferation [19, 21], we examined whether in-
creasing the b-catenin level would be sufficient to drive
neonatal cardiomyocytes into cell cycle entry. FRATtide
[22] is a peptide fragment corresponding to residues
188–226 of the gene named frequently rearranged in
advanced T cell lymphomas 1 (FRAT1). FRATtide binds
to the carboxy terminus of GSK-3 and inhibits the ability
of GSK-3 to phosphorylate and thus inactivate b-catenin
[22, 23]. Interestingly, FRATtide does not appear to af-
fect other phosphorylation substrates of GSK-3, such
as glycogen synthase [22]. Cardiomyocytes treated
with FRATtide and labeled with BrdU for 72 hr exhibited
a BrdU incorporation rate of 24.6%6 1.5%, representing
an almost 2-fold increase over the control (14.6% 6
2.2%, p = 0.0045) (Figure 3C). Our results suggest that
BIO stimulation elevates b-catenin activity in neonatal
cardiomyocytes, and that this may account, in part, for
the increased proliferative ability of the cells.
BIO Induces Adult Mammalian Cardiomyocytes to
Dedifferentiate and Undergo Mitosis
In neonatal cardiomyocytes, the presence of BIO in-
duces the cells to undergo cell cycle progression.
Thus, we examined whether BIO has a similar effect
in adult rat cardiomyocytes. To determine if BIO can
induce S phase entry, adult cells were labeled withBrdU for 6 days. Cardiomyocytes were identified by their
specific stainings for the cardiac contractile apparatus
proteins tropomyosin or Troponin T. Control cells had
a low rate of BrdU incorporation (1.2% 6 0.2%) after 6
days of BrdU labeling (Figure 4A). Treatment with MeBIO
shows a comparably low rate. In contrast, stimulation of
cardiomyocytes with 5 mM BIO increased the BrdU in-
corporation rate 10-fold to 13.1% 6 1.7% compared to
the control (p = 0.0003). Similarly, results were observed
after 9 days of labeling (data not shown). Thus, the stim-
ulation of adult cardiomyocytes with BIO can induce S
phase entry.
We performed H3P analyses to determine whether
BIO-stimulated adult rat cardiomyocytes are able to un-
dergo mitosis. After 6 days of culture, only 0.1%6 0.1%
of control cells stained positive for H3P. When stimu-
lated with BIO, the percentage of H3P-positive cells
increased to 2.41% 6 0.8% (p = 0.007) (Figure 4B).
Furthermore, we observed adult cardiomyocytes at
different stages of mitosis (Figure 4C). Importantly, the
adult cardiomyocytes that are induced to undergo mito-
sis have similar morphology to the nondividing cardio-
myocytes and thus do not appear to represent a specific
subpopulation of cells. Together, our data indicate that
adult cardiomyocytes stimulated with BIO can undergo
cell cycle progression.
Previously, we showed that FGF1-mediated prolifera-
tion of adult cardiomyocytes enabled by p38 MAPK
inhibition results in a transient dedifferentiation of myo-
fibrillar structure during cell division [5]. In culture, there
is a gradual spreading of the adult rat cardiomyocytes,
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(A–D) Adult rat cardiomyocytes were stimulated with DMSO (control) or 5 mM BIO every 3 days and were assayed for cell cycle progression
after 6 days. (A) Cells were labeled with BrdU for 6 days. Treatment of cardiomyocytes with BIO significantly increased the percentage of cells
that labeled positively with BrdU as compared to control cells (mean 6 SD). (B) H3P analyses were performed to determine whether BIO-stim-
ulated cells are able to undergo mitosis. After 6 days, 0.1% 6 0.09% of the control cells stained positive for H3P. When treated with BIO, the
percentage of H3P-positive cells increased 20-fold (mean 6 SD). (C) Adult cardiomyocytes at different stages of mitosis detected with H3P
(green), tropomyosin (red), and DNA (blue). (D) Cells treated with DMSO (top panels) contain well-organized myofibrils and show striations
formed by Z-discs when stained with the sarcomeric marker Troponin T (red). Cells treated with BIO have disorganized myofibrils oriented
randomly with no apparent striations (lower panels). DNA is shown in blue. The scale bars are 20 mm in (C) and 40 mm in (D).leading to a loss of the rod-shaped morphology. Impor-
tantly, control adult cardiomyocytes maintain a well-
organized contractile apparatus (myofibrils) with stria-
tions, as visualized with the sarcomeric marker Troponin
T (Figure 4D, top panel). In contrast, BIO-treated cells
have a disorganized myofibrillar architecture with few
striations, independent of cell cycle state (Figure 4D,
bottom panel). It has been postulated that the well-orga-
nized contractile architecture of adult cardiomyocytes
may physically impede the kinetics of cell division [24].
For example, newt cardiomyocytes completely lose
striation during division [25]. Moreover, the loss of the
hallmark myofibrillar structure has been described as
‘‘dedifferentiation’’ [26–28]. Thus, BIO-induced dediffer-
entiation may potentiate proliferation of adult cardio-
myocytes by facilitating cell division.
Discussion
Our results demonstrate that the small molecule BIO can
increase the proliferative ability of mammalian cardio-
myocytes. Furthermore, the results reported in this
paper, together with the work of Sato and colleagues,provide proof of principle that a pharmacological inhib-
itor, BIO, can maintain self-renewal and pluripotency in
ESCs and promote dedifferentiation and proliferation
in terminally differentiated cardiomyocytes. The effect
of BIO can be attributed to the inhibition of GSK-3 func-
tion in cardiomyocytes; thus, we have identified a previ-
ously uncharacterized function for GSK-3 in regulating
mammalian cardiomyocyte proliferation.
Several lines of evidence have indicated that GSK-3b
can act as a negative regulator of hypertrophy in mam-
malian hearts both during development and in response
to several forms of pathological stress (for a review, see
[29]). However, these studies all utilize overexpression
technology. To date, the native role of GSK-3 in the heart
has not been examined. If GSK-3 acts endogenously as
a negative growth regulator, then it can be predicted
that loss of GSK-3 activity in cardiomyocytes would
cause an increase in cell size. Surprisingly, cardiomyo-
cytes that are treated with BIO are not larger than control
cells in vitro. Rather, they appear to be slightly smaller in
size (data not shown). This observation suggests that
endogenous GSK-3 may not normally function to inhibit
growth, at least in our culture system. Our data also
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cal Wnt signaling may play a role in preventing cardio-
myocytes from undergoing cell division postbirth.
One potential pathway with which BIO may interact to
regulate cardiomyocyte proliferation is the p38 MAPK
pathway. Inhibition of p38 MAPK activity has been
shown to promote mammalian cardiomyocyte prolifera-
tion [5]. To test this possibility, we assayed for changes
in p38 MAPK in response to BIO treatment in vitro. There
were no detectable differences in the phosphorylation
state of p38 between BIO, MeBIO, or control-treated
cardiomyocytes (data not shown). Similar results were
obtained when we assayed for p38 MAPK activity. While
we have not observed any detectable changes in p38
MAPK under the conditions tested, it is possible that
BIO may interact with the p38 MAPK pathway down-
stream of the kinase itself. However, our results suggest
that BIO does not regulate p38 MAPK activity in promot-
ing proliferation in mammalian cardiomyocytes.
Our findings that BIO increases the proliferative ca-
pacity of cardiomyocytes in vitro validates the use of
chemical genetics as an excellent and rapid approach
by which to identify and modulate pathways involved
in cardiac regeneration. The use of pharmacological
tools bypasses the requirement for generating genetic
and molecular reagents and will expand our ability to
characterize the biology of mammalian cardiomyocytes.
Finally, our identification of a mechanism that is able
to increase cardiac proliferative potential in vitro is an
important step toward the understanding of signaling
pathways and their interactions that are required for
heart regeneration. Furthermore, the results of this
study, together with the work of Sato and coworkers
[7], demonstrate that a pharmacological inhibitor, BIO,
can maintain pluripotent self-renewal in ESCs and
promote dedifferentiation and proliferation in terminally
differentiated cardiomyocytes. Additional studies are
needed to determine if BIO’s functions are recapitulated
both in stem cells and cardiomyocytes in animals.
Nevertheless, the identification of a dual role for BIO
suggests that the maintenance of stem cell properties
and the induction of proliferation in differentiated cardi-
omyocytes may share common molecular pathways.
The demonstration of this concept might alter our
approach to identify therapeutic compounds that can
restore function in the diseased heart.
Significance
Heart disease results in the loss of cardiomyocytes
and is a leading cause of death. It is generally believed
that the adult mammalian cardiomyocytes are unable
to divide; thus, it is a significant challenge to develop
effective therapies. A major approach is to generate
new cardiomyocytes from stem cells. Alternatively,
we have demonstrated that it is possible to induce pro-
liferation in existing mammalian cardiomyocytes, and
we sought to identifymechanisms involved in this pro-
cess. Interestingly, the maintenance of self-renewal in
stem cells has generally been thought of as a process
that is distinct from that of the induction of prolifera-
tion in postmitotic mammalian cells, even though the
requirement for proliferation is a necessary step in
both events. Whether these two processes share com-monmolecular pathways is an important question that
has not been addressed by existing studies, and it has
strong implications for future therapeutic approaches.
To our knowledge, the small molecule GSK-3 inhibitor,
BIO, is the first pharmacological agent shown to main-
tain self-renewal in human andmouse ESCs. We show
that BIO promotes proliferation in mammalian cardio-
myocytes. Stimulation of neonatal rat cardiomyocytes
with BIO induced cell cycle entry and the upregulation
of positive cell cycle regulators, while the level of a
CDK inhibitor p27 was decreased. BIO treatment ele-
vated b-catenin activity in cardiomyocytes, suggest-
ing that the increase in proliferative ability may be
partly due to the activation of the canonical Wnt path-
way. In both neonatal and adult rat cardiomyocytes,
BIO stimulation promoted cell cycle progression and
increased the number of mitoses. The ability of BIO
to promote proliferation of cardiomyocytes defines
a new signaling pathway, GSK-3, in regeneration. Fur-
thermore, our demonstration of a second role for BIO
suggests that the maintenance of stem cell self-re-
newal and the induction of proliferation in differenti-
ated cardiomyocytes may share common molecular
pathways.
Experimental Procedures
Culture of Mammalian Cardiomyocytes
Animal experiments were performed in accordance with guidelines
of Children’s Hospital, Boston. Rat ventricular cardiomyocytes
from 2- to 3-day-old Wistar rats were isolated and cultured as de-
scribed [5]. Adult cardiomyocytes from 3-month-old male rats
were cultured for 1 day after isolation and were treated every 3
days with the appropriate compounds in the same medium supple-
mented with 2 mM glutamine as described [5]. BIO was purchased
from EMD Biosciences and was dissolved in DMSO. In our primary
cultures, more than 90% of the cells are myocytes, as evaluated
by indirect immunofluorescence staining with an antibody to sarco-
meric tropomyosin [5].
Immunofluorescence Stainings
Primary antibodies used include: rat anti-BrdU (Abcam), rabbit anti-
Cyclin A (Cell Signaling), mouse anti-Cyclin D1 (Cell Signaling),
mouse anti-p27 (BD Transduction Laboratories), rabbit anti-Ki67
(Abcam), rabbit anti-phospho-Histone H3 (Upstate Signaling), rabbit
anti-b-catenin (BD Transduction Laboratories), and mouse anti-
tropomyosin (Developmental Hybridoma Studies Bank). Secondary
antibodies conjugated to Alexa fluorophores were used for signal
detection (Invitrogen). DNA was visualized with DAPI (40,60-diami-
dino-2-phenylindole, 0.5 mg/ml; Sigma). Stainings were performed
as described [5].
Luciferase Assays
A total of 40 mg TOPflash or FOPflash reporter plasmids (Upstate
Signaling) were cotransfected with 4 mg pGL4.75 [hRluc/CMV] vec-
tor (Promega) into 23 106 neonatal cardiomyocytes using the Nucle-
ofector Kit (Amaxa) and were plated in 24-well plates. Cells were
cultured for 3 days and were subsequently stimulated with selected
compounds for 24 hr. Reporter activity was measured by using the
Dual Luciferase Assay System (Promega). TOPflash or FOPflash ac-
tivity was normalized to the measured Renilla luciferase activity of
pGL4.75, an internal standard for transfection efficiency.
Statistical Analysis
Data were analyzed with a two-tailed Student’s t test. Each experi-
ment was performed at least three times (nR 3), and the results re-
ported are statistically significant (p % 0.05). Standard deviations
(6SD) are given for each mean value. For immunofluorescence anal-
yses, 500 or more cells were analyzed per experiment for neonatal
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963cardiomyocytes, and at least 500 (BrdU) or 1000 cells (H3P) per
experiment were analyzed for adult cardiomyocytes.
Supplemental Data
Supplemental Data include a table showing the percentage of
BrdU incorporation of cardiomyocytes under conditions tested and
are available at http://www.chembiol.com/cgi/content/full/13/9/
957/DC1/.
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